FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2805592007> ?p ?o ?g. }

• W2805592007 endingPage "952" @default.
• W2805592007 startingPage "940" @default.
• W2805592007 abstract "Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population.KEYNOTE-224 is a non-randomised, multicentre, open-label, phase 2 trial that is set in 47 medical centres and hospitals across ten countries. Eligible patients had pathologically confirmed hepatocellular carcinoma; had previously been treated with sorafenib and were either intolerant to this treatment or showed radiographic progression of their disease after treatment; an Eastern Cooperative Oncology Group performance status of 0-1; adequate organ function, and were Child-Pugh class A. Participants received 200 mg pembrolizumab intravenously every 3 weeks for about 2 years or until disease progression, unacceptable toxicity, patient withdrawal, or investigator decision. The primary endpoint was objective response, defined as the proportion of patients with complete or partial response in all patients who received at least one dose of pembrolizumab, which was radiologically confirmed by use of the Response Evaluation Criteria in Solid Tumors version 1.1 by central review. Safety was also assessed in all treated patients. This trial is ongoing but closed to enrolment and is registered with ClinicalTrials.gov number NCT02702414.Between June 7, 2016, and Feb 9, 2017, we screened 169 patients with advanced hepatocellular carcinoma, of whom 104 eligible patients were enrolled and treated. As of data cutoff on Feb 13, 2018, 17 (16%) patients were still receiving pembrolizumab. We recorded an objective response in 18 (17%; 95% CI 11-26) of 104 patients. The best overall responses were one (1%) complete and 17 (16%) partial responses; meanwhile, 46 (44%) patients had stable disease, 34 (33%) had progressive disease, and six (6%) patients who did not have a post-baseline assessment on the cutoff date were considered not to be assessable. Treatment-related adverse events occurred in 76 (73%) of 104 patients, which were serious in 16 (15%) patients. Grade 3 treatment-related events were reported in 25 (24%) of the 104 patients; the most common were increased aspartate aminotransferase concentration in seven (7%) patients, increased alanine aminotransferase concentration in four (4%) patients, and fatigue in four (4%) patients. One (1%) grade 4 treatment-related event of hyperbilirubinaemia occurred. One death associated with ulcerative oesophagitis was attributed to treatment. Immune-mediated hepatitis occurred in three (3%) patients, but there were no reported cases of viral flares.Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib. These results indicate that pembrolizumab might be a treatment option for these patients. This drug is undergoing further assessment in two phase 3, randomised trials as a second-line treatment in patients with hepatocellular carcinoma.Merck & Co, Inc." @default.
• W2805592007 created "2018-06-13" @default.
• W2805592007 creator A5001010553 @default.
• W2805592007 creator A5001493210 @default.
• W2805592007 creator A5001637416 @default.
• W2805592007 creator A5002648450 @default.
• W2805592007 creator A5005775401 @default.
• W2805592007 creator A5006506843 @default.
• W2805592007 creator A5008662566 @default.
• W2805592007 creator A5008933620 @default.
• W2805592007 creator A5011606139 @default.
• W2805592007 creator A5013636222 @default.
• W2805592007 creator A5014964145 @default.
• W2805592007 creator A5015963238 @default.
• W2805592007 creator A5016540674 @default.
• W2805592007 creator A5017504528 @default.
• W2805592007 creator A5019481117 @default.
• W2805592007 creator A5019666497 @default.
• W2805592007 creator A5020985866 @default.
• W2805592007 creator A5021028061 @default.
• W2805592007 creator A5023523894 @default.
• W2805592007 creator A5025272654 @default.
• W2805592007 creator A5026725352 @default.
• W2805592007 creator A5029171331 @default.
• W2805592007 creator A5030492549 @default.
• W2805592007 creator A5031063478 @default.
• W2805592007 creator A5031212154 @default.
• W2805592007 creator A5032900701 @default.
• W2805592007 creator A5034318383 @default.
• W2805592007 creator A5034356923 @default.
• W2805592007 creator A5036130262 @default.
• W2805592007 creator A5036400761 @default.
• W2805592007 creator A5037784680 @default.
• W2805592007 creator A5037815003 @default.
• W2805592007 creator A5037942451 @default.
• W2805592007 creator A5038198711 @default.
• W2805592007 creator A5041925723 @default.
• W2805592007 creator A5043245662 @default.
• W2805592007 creator A5046498356 @default.
• W2805592007 creator A5046513148 @default.
• W2805592007 creator A5046656967 @default.
• W2805592007 creator A5047736184 @default.
• W2805592007 creator A5052563056 @default.
• W2805592007 creator A5053037783 @default.
• W2805592007 creator A5060744664 @default.
• W2805592007 creator A5061222063 @default.
• W2805592007 creator A5062964130 @default.
• W2805592007 creator A5063920774 @default.
• W2805592007 creator A5063997602 @default.
• W2805592007 creator A5068644454 @default.
• W2805592007 creator A5069522018 @default.
• W2805592007 creator A5071892047 @default.
• W2805592007 creator A5073989429 @default.
• W2805592007 creator A5079645039 @default.
• W2805592007 creator A5082631947 @default.
• W2805592007 creator A5085357579 @default.
• W2805592007 creator A5086023651 @default.
• W2805592007 creator A5087844014 @default.
• W2805592007 creator A5088566246 @default.
• W2805592007 creator A5089670001 @default.
• W2805592007 creator A5090372851 @default.
• W2805592007 date "2018-07-01" @default.
• W2805592007 modified "2023-10-18" @default.
• W2805592007 title "Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial" @default.
• W2805592007 cites W1863396492 @default.
• W2805592007 cites W1940241680 @default.
• W2805592007 cites W1971837077 @default.
• W2805592007 cites W1982488143 @default.
• W2805592007 cites W1994193851 @default.
• W2805592007 cites W2009671859 @default.
• W2805592007 cites W2019607817 @default.
• W2805592007 cites W2052730188 @default.
• W2805592007 cites W2060070314 @default.
• W2805592007 cites W2079586464 @default.
• W2805592007 cites W2107564997 @default.
• W2805592007 cites W2137591261 @default.
• W2805592007 cites W2153778867 @default.
• W2805592007 cites W2162667703 @default.
• W2805592007 cites W2194546364 @default.
• W2805592007 cites W2516096091 @default.
• W2805592007 cites W2527905628 @default.
• W2805592007 cites W2560499218 @default.
• W2805592007 cites W2606367731 @default.
• W2805592007 cites W2624831627 @default.
• W2805592007 cites W2739132742 @default.
• W2805592007 cites W2759382352 @default.
• W2805592007 cites W2779747165 @default.
• W2805592007 cites W2787358630 @default.
• W2805592007 cites W2792376809 @default.
• W2805592007 cites W2792999042 @default.
• W2805592007 cites W634312238 @default.
• W2805592007 doi "https://doi.org/10.1016/s1470-2045(18)30351-6" @default.
• W2805592007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29875066" @default.
• W2805592007 hasPublicationYear "2018" @default.
• W2805592007 type Work @default.
• W2805592007 sameAs 2805592007 @default.
• W2805592007 citedByCount "1661" @default.
• W2805592007 countsByYear W28055920072018 @default.

• next